Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1276 to 1290 of 1300 results for heart OR cardi* OR arrythmia

  1. NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation

    NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).

  2. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  3. Weight management: BMI recording (long term conditions) (IND320)

    This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  4. NICE recommends innovative treatment for severe blood disorder for NHS use

    Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.

  5. New treatment option for adults with obesity and non-diabetic hyperglycaemia

    All eligibility criteria must be met for Liraglutide to be offered.

  6. New treatment option recommended for people with type 2 diabetes

    Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.

  7. People at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.

  8. Speaking with one language: How using a common data model might speed up decision making

    The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.

  9. Updated menopause guidance includes discussion aid to support conversations about HRT

    Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.

  10. More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes

    Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.

  11. Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%

    Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.

  12. Consultation on updated guideline to assess and prevent falls in older people

    We're seeking views from healthcare professionals and the public on draft recommendations covering assessments and interventions to reduce the risk of falls in older people.

  13. Consultation on NHS England proposals for a phased launch of obesity injection

    Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.

  14. More than 40,000 people could benefit after NICE recommends new 'take at home' pill for advanced prostate cancer

    Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.

  15. Towards a new partnership – NICE and the voluntary and community sector

    Victoria Thomas gives details of NICE’s new voluntary and community sector forum.